- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Tharimmune Inc.: Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting to Support TH104 for Chronic Pruritus in Chronic Liver Disease | 106 | ACCESSWIRE | Significant correlation shown between blood levels and symptom relief; TH104 was well tolerated with no unexpected treatment-emergent adverse eventsPhase 2 preliminary data for chronic pruritus in primary... ► Artikel lesen | |
| 13.11. | Tharimmune COO Appajosyula Sireesh erwirbt Aktien im Wert von 10.096 US-Dollar | 2 | Investing.com Deutsch | ||
| 13.11. | Tharimmune erhält europäisches Patent für Krebstherapie-Technologie | 2 | Investing.com Deutsch | ||
| THARIMMUNE Aktie jetzt für 0€ handeln | |||||
| 13.11. | Tharimmune set to receive European patent for cancer therapy tech | 2 | Investing.com | ||
| 13.11. | Tharimmune Inc.: Tharimmune Granted European Patent for Delivery of Optimized Molecularly Targeted Therapeutics | 170 | ACCESSWIRE | BRIDGEWATER, NJ / ACCESSWIRE / November 13, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates... ► Artikel lesen | |
| 07.11. | Tharimmune, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 04.11. | Tharimmune Inc.: Tharimmune Announces Upcoming Conference Presentations | 146 | ACCESSWIRE | BRIDGEWATER, NJ / ACCESSWIRE / November 4, 2024 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates... ► Artikel lesen | |
| 30.10. | What's Going On With Tharimmune Shares Wednesday? | 2 | Benzinga.com | ||
| 30.10. | Tharimmune secures EMA feedback on pruritus drug trial | 3 | Investing.com | ||
| 30.10. | Tharimmune erhält positives Feedback der EMA für Pruritus-Medikamententest | 9 | Investing.com Deutsch | ||
| 30.10. | Tharimmune Inc.: Tharimmune Receives Positive Regulatory Feedback From EMA for TH104 Clinical Program for Chronic Pruritus in Primary Biliary Cholangitis | 184 | ACCESSWIRE | BRIDGEWATER, NJ / ACCESSWIRE / October 30, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates... ► Artikel lesen | |
| 28.10. | Tharimmune Inc.: Tharimmune Presents Favorable TH104 Phase 1 Clinical Data at the American College of Gastroenterology 2024 Annual Scientific Meeting | 267 | ACCESSWIRE | TH104, the Company's lead candidate for moderate-to-severe pruritus in chronic liver disease, showed no opioid withdrawal effects, reinforcing safety profileTH104 was well tolerated with no unexpected... ► Artikel lesen | |
| 25.10. | Tharimmune Inc.: Tharimmune Announces Upcoming Conference Presentations | 203 | ACCESSWIRE | BRIDGEWATER, NJ / ACCESSWIRE / October 25, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates... ► Artikel lesen | |
| 03.10. | Hillstream Biopharma stock plunges to 52-week low of $2.23 | 2 | Investing.com | ||
| 03.10. | Hillstream Biopharma-Aktie stürzt auf 52-Wochen-Tief von 2,23 US-Dollar | 1 | Investing.com Deutsch | ||
| 30.09. | Tharimmune, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 30.09. | Hillstream Biopharma: Tharimmune Signs Nonbinding Letter of Intent to Merge With Intract Pharma to Create Transformative Oral Biologic Therapeutics Company | 243 | ACCESSWIRE | - Business combination to form a best-in-class, transformative oral biologics company - Synergies between Tharimmune's clinical-stage assets and Intract's delivery platform to drive pipeline growth... ► Artikel lesen | |
| 25.09. | Hillstream Biopharma stock plunges to 52-week low of $2.52 | 2 | Investing.com | ||
| 25.09. | Hillstream Biopharma-Aktie stürzt auf 52-Wochen-Tief von 2,52 US-Dollar | 1 | Investing.com Deutsch | ||
| 16.09. | Tharimmune, Inc. - 8-K, Current Report | 1 | SEC Filings |
Seite:
1 2 3 Weiter >>
43 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 9,915 | +0,10 % | KURSEXPLOSION bei Biotech-Aktie! BioNTech, Evotec, Nyxoah | Geht es bei Evotec jetzt doch ganz schnell? Ein Finanzinvestor positioniert sich jedenfalls für eine Übernahme und die Aktie schoss zuletzt kräftig nach oben. Ist damit die Enttäuschung über die Quartalszahlen... ► Artikel lesen | |
| CORE ONE LABS | 0,079 | 0,00 % | New Core One 3D Printer From Prusa May Be the Answer to Its Bambu Problem | ||
| MAINZ BIOMED | 0,205 | -2,61 % | Mainz Biomed und Thermo Fisher Scientific unterzeichnen Kooperationsvereinbarung | ||
| TREVENA | 0,153 | 0,00 % | Trevena Inc.: Trevena Reports Third Quarter 2024 Results and Provides Business Update | CHESTERBROOK, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with... ► Artikel lesen | |
| CENTOGENE | 0,070 | -1,41 % | Centogene NV: CENTOGENE Signs Strategic Transaction With Private Equity Group Charme Capital Partners | CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (OTC: CNTGF) ("CENTOGENE" or the "Company"), the essential life science partner for data-driven answers... ► Artikel lesen | |
| GALAPAGOS NV | 24,060 | +0,08 % | GALAPAGOS NV - S-8, Securities to be offered to employees in employee benefit plans | ||
| CELLECTAR BIOSCIENCES | 1,380 | -6,76 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides a Corporate Update | Phase 2 CLOVER-WaM pivotal study data selected for oral presentation at 66th Annual American Society of Hematology Meeting and Exposition Raised approximately $19.4 million with potential to raise... ► Artikel lesen | |
| SENSEI BIOTHERAPEUTICS | 0,470 | +1,29 % | Sensei Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights | - SNS-101 Phase 1/2 dose expansion clinical data expected in the first half of 2025 - - Organizational restructuring to focus resources on advancing the clinical development of SNS-101 - ... ► Artikel lesen | |
| AC IMMUNE | 3,015 | -1,47 % | AC Immune stock jumps 20% on data for Parkinson's disease drug | ||
| CHIMERIX | 0,847 | +1,07 % | Chimerix, Inc.: Chimerix Announces Updated Phase 2 Response Assessment of Dordaviprone in Recurrent H3 K27M Glioma at the 2024 SNO Meeting | DURHAM, N.C., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 0,821 | -0,06 % | CytomX Therapeutics Inc.: CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY, in a Phase 1 Study in Patients with Solid Tumors | SOUTH SAN FRANCISCO, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced... ► Artikel lesen | |
| CYTOKINETICS | 48,000 | +1,27 % | Pharma-Offensive: Bayer schließt Millionen-Deal mit Cytokinetics - Rettung oder Risiko? | © Foto: picture alliance / Rupert Oberhäuser | Rupert OberhäuserBayer stärkt mit einem Millionen-Deal sein Herz-Kreislauf-Portfolio, doch Analysten bleiben skeptisch: Rechtsstreitigkeiten und Gewinne... ► Artikel lesen | |
| SPERO THERAPEUTICS | 1,122 | -1,92 % | Spero Therapeutics, Inc.: Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update | Phase 3 PIVOT-PO trial of tebipenem HBr remains on track to complete enrollment in 2H 2025 Reiterate cash runway into mid-2026; Q3 2024 ending cash balance of $76.3M CAMBRIDGE, Mass., Nov.... ► Artikel lesen | |
| EIGER BIOPHARMACEUTICALS | 5,840 | 0,00 % | Eiger BioPharmaceuticals: Zock-Tipp liefert +864% in zweieinhalb Monaten | "In zwei Wochen winkt ein Börsenbeben", titelten wir zuletzt in weiser Voraussicht. Tatsächlich geht unser spekulativer Volltreffer Eiger BioPharmaceuticals (WKN: A3EKZU) allein gestern noch einmal... ► Artikel lesen | |
| PULMATRIX | 5,700 | +6,54 % | Pulmatrix: Über +100% Rendite für Anlegerclub NBC | Der No Brainer Club (NBC) hat erneut einen Volltreffer gelandet. Die Pulmatrix-Aktie, die Abonnenten des exklusiven Anlegerclubs im Frühsommer vorgestellt wurde, ist am Mittwoch zeitweise um über +100%... ► Artikel lesen |
THARIMMUNE INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -4,72 % bei einem Aktienkurs von 2,420 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu THARIMMUNE INC finden Sie auf Wallstreet Online.
